CAMBRIDGE, England & PARIS--(BUSINESS WIRE)--Novacyt (NYSE-ALTERNEXT: ALNOV), a leading diagnostics manufacturer that develops and markets innovative solutions in liquid-based cytology for the detection of cancer, including cervical cancer and all the other non-gynaecological cancers, announces its plans to combine in a stock-for-stock transaction with Lab21, the Cambridge, UK-based global specialist in personalised medicine and clinical diagnostics.
Help employers find you! Check out all the jobs and post your resume.
